These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7591885)

  • 1. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients.
    Sandler HM; McLaughlin PW; Ten Haken RK; Addison H; Forman J; Lichter A
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):797-801. PubMed ID: 7591885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?
    Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V
    Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
    Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
    Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer.
    Fukunaga-Johnson N; Sandler HM; McLaughlin PW; Strawderman MS; Grijalva KH; Kish KE; Lichter AS
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):311-7. PubMed ID: 9226317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
    Zelefsky MJ; Leibel SA; Kutcher GJ; Kelson S; Ling CC; Fuks Z
    Cancer J Sci Am; 1995; 1(2):142-50. PubMed ID: 9166467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
    Lee CM; Lee RJ; Handrahan DL; Sause WT
    Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
    Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A; Johannessen DC; Muren LP; Wentzel-Larsen T; Dahl O
    Radiother Oncol; 2004 Apr; 71(1):43-53. PubMed ID: 15066295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.